Generex Biotechnology Corporation

626 articles with Generex Biotechnology Corporation

• Generex Biotechnology Corporation Subsidiary, Olaregen Therapeutix Announces its Malaysian Distribution Partner, Nexgen Medical

  7/26/2021

  Generex Biotechnology Corporation announced in May that the company has executed a Distribution Agreement with Nexgen Medical Sdn Bhd, Inc.

• Generex Biotechnology Subsidiary NuGenHealth Contracts with Westside Medicine & Cardiology, Inc. to Provide Remote Patient Monitoring (RPM) Services

  5/11/2021

  Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex” or the “Company”), an innovative and integrated healthcare holding company with end-to-end solutions for patient centric care including the development of its innovative “Complete Vaccine™” to fight SARS-CoV-2, announced today that its subsidiary NuGenHealth has signed a contract with Westside Medicine & Cardiology, Inc.

• Generex Posts Recording of May 6 Shareholder Conference Call Highlighting its Ii-Key COVID Complete Vaccine™ and its Go-Forward Plans for Revenue Producing Assets

  5/10/2021

  Update on Ii-Key-SARS-CoV-2 vaccine program Appointment of Dr. Craig Eagle to be Chairman of the Board of NuGenerex Immuno-Oncology Inc. pending board approval. Re-Launch of Excellagen® in the VA Hospital Network Launch of Remote Patient Monitoring (RPM) Business NuGenHealth Update on Partnership & Anticipated Acquisition of AltuCell

• Generex Biotechnology Subsidiary NuGenHealth Contracts with Florida Health Care Associates to Provide Remote Patient Monitoring (RPM) Services

  5/6/2021

  Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex” or the “Company”), an innovative and integrated healthcare holding company with end-to-end solutions for patient centric care including the development of its innovative “Complete Vaccine” to fight SARS-CoV-2, announces today that its subsidiary NuGenHealth has signed a contract with Florida Health Care Associates (FHCA)

• Generex Provides Clarification on Its Ii-Key COVID-19 Complete Vaccine China Partnership Agreement

  5/5/2021

  Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex” or the “Company”), an innovative and integrated healthcare holding company with end-to-end solutions for patient centric care including the development of its innovative “Complete Vaccine” to fight SARS-CoV-2, today provided guidance on the terms of its agreement with Beijing Youfeng Biological Technology,

• Generex Biotechnology Announces Call-in Details and Agenda for Shareholder Conference Call on Thursday May 6, 2021 at 9:00 AM

  5/4/2021

  Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex” or the “Company”), an innovative and integrated healthcare holding company with end-to-end solutions for patient centric care including the development of its innovative “Complete Vaccine” to fight SARS-CoV-2, today announced the call in details and an updated agenda for the shareholder conference call on Thursday May 6, 2021 at 9:00 AM.

• Generex Biotechnology Subsidiary Olaregen Therapeutix Announces Agreement with Nexgen Medical for Distribution of Excellagen® Wound Conforming Matrix in Malaysia

  5/3/2021

  Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) subsidiary Olaregen Therapeutix today announced that the company has executed a Distribution Agreement with Nexgen Medical Sdn Bhd, Inc. (“Nexgen”) to be Generex’s exclusive distributor to import, market and sell the Excellagen line of wound care products in Malaysia.

• Generex Provides Update on its Ii-Key COVID-19 Complete Vaccine Program: Advancing Global Development

  4/27/2021

  Generex receives $2 million payment from Chinese partners to provide research results, data, and necessary documents to support an IND submission to the Chinese National Medical Products Administration (NMPA)

• Generex Biotechnology Announces Shareholder Conference Call Scheduled for Thursday May 6, 2021

  3/31/2021

  Generex Biotechnology Corporation (OTCQB: GNBT) (“Generex or the “Company”), an innovative and integrated healthcare holding company with end-to-end solutions for patient centric care including the development of its innovative “Complete Vaccine” to fight SARS-CoV-2, today announced that it will hold a shareholder conference call on Thursday May 6, 2021 at 9:00 AM ET.

• Generex and NuGenerex Immuno-Oncology Provide Update on Ii-Key COVID-19 Complete Vaccine™ Development Program

  2/24/2021

  Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT)  (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has completed the mouse immunogenicity study with transgenic mice that have been genetically engineered with a gene from the human immune system called the DR4 human leukocyte antigen (HLA) allele

• Generex Biotechnology Announces Call-in Details and Agenda for Shareholder Conference Call on Friday February 5, 2021 at 9:00 AM

  2/3/2021

  Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced the call-in information and an updated agenda for the shareholder conference call on Friday February 5th at 9:00 am.

• Generex Biotechnology Announces Investor Conference Call Scheduled for Friday February 5, 2021 at 9:00 AM

  1/8/2021

  Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) today announced that it will hold an investor conference call on Friday February 5, 2021 at 9:00 AM. Joseph Moscato, Generex President & Chief Executive Officer stated: “I am excited to give our first shareholder conference call to update investors about the development of our Ii-Key complete vaccine against the SARS-CoV-2 coronavirus that continues to ravage the world. We

• Generex and NuGenerex Immuno-Oncology Provide Update on Ii-Key COVID-19 Vaccine Development Program and Files Trademark Application for The Complete Vaccine™

  12/31/2020

  Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that its majority owned public entity, NuGenerex Immuno-Oncology, Inc. (NGIO), has filed for and expects to receive a trademark for The Complete Vaccine™

• Generex and NuGenerex Immuno-Oncology Ii-Key-SARS-CoV-2 Vaccine Partner Bintai Kinden Executes its Exclusive Distribution & Licensing Option for Australia and New Zealand

  11/23/2020

  Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) and subsidiary NuGenerex Immuno-Oncology today announced that their Ii-Key COVID-19 vaccine development partner Bintai Kinden Corporation and its subsidiary BINTAI HEALTHCARE SDN.

• Generex signs Worldwide Licensing Deal with China Partners on the Development of an Ii-Key-H1 Swine Influenza Vaccine

  11/19/2020

  Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company has signed a worldwide Licensing and Development Agreement with a consortium of partners in China to utilize the Ii-Key vaccine platform technology from Generex subsidiary NuGenerex Immuno-Oncology (NGIO) for developing a vaccine against the G4 EA H1N1 swine influenza that is rapidly emerging in China.

• Generex Inks $50 Million Licensing Deal with China Partners on the Cooperative Development of the Ii-Key Vaccine Platform

  11/18/2020

  Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company has closed a $50 million Licensing and Development Agreement with a consortium of partners in China for the Ii-Key vaccine platform technology from Generex subsidiary NuGenerex Immuno-Oncology (NGIO)

• Generex Biotechnology Announces Interview with Richard Purcell EVP of R&D on the Yo! Dr.Yo Show with an Update on the Ii-Key COVID Vaccine ProgramLivestream Interview on Friday November 13 at 2 PM EST

  11/12/2020

  Generex Biotechnology Corporation (OTCQB:GNBT) today announced that Richard Purcell, Executive Vice President of Research & Development at Generex and NuGenerex Immuno-Oncology will be featured on the Yo! Dr. Yo Show to provide an update on the company’s COVID-19 vaccine development program.

• Generex Announces the Signing of a Framework Agreement with The China CDC, Beijing Guoxin Haixiang Equity Investment Partnership and Beijing Youfeng International Consulting Co., Ltd on the Cooperative Development of Ii-Key Vaccines

  11/4/2020

  Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has signed a Framework Agreement with the China CDC, Beijing Guoxin Haixiang Equity Investment Partnership, and Beijing Youfeng International Consulting Co., Ltd for the development and commercialization of the Ii-Key-SARS-CoV-2 coronavirus vaccine in China.

• NuGenerex Immuno-Oncology Announces the Launch of a New Corporate Website

  11/3/2020

  NuGenerex Immuno-Oncology (NGIO), a subsidiary of Generex Biotechnology Corporation pleased to announce that the company has launched its new corporate website to provide investors with information on the NGIO mission, management, and pipeline for the Ii-Key vaccine platform for cancer and infectious disease.

• Generex Subsidiary NuGenerex Immuno-Oncology Announces Appointment of Dr. Tamera Coyne-Beasley to the Scientific Advisory Board for its COVID-19 Vaccine Development Program

  10/30/2020

  -Dr. Tamera Coyne-Beasley, MD, MPH, FAAP, FSAHM is the Derrol Dawkins, MD Endowed Chair in Adolescent Medicine at Children’s of Alabama, Professor of Pediatrics and Internal Medicine, Director of the University of Alabama at Birmingham Division of Adolescent Medicine, and Vice Chair of Pediatrics for Community Engagement